128 1. Aspetti Generali of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). Blood [Internet]. 2011 Aug 4 [cited 2022 Jun 19];118(5):1413–20. Available from: https://ashpublications.org/blood/article/118/5/1413/28987/ Long-term-health-related-outcomes-in-survivors-of 39. Bhatia S, Davies SM, Scott Baker K, Pulsipher MA, Hansen JA. NCI, NHLBI first international consensus conference on late effects after pediatric hematopoietic cell transplantation: etiology and pathogenesis of late effects after HCT performed in childhood--methodologic challenges. Biol Blood Marrow Transplant [Internet]. 2011 Oct [cited 2022 Jun 19];17(10):1428–35. Available from: https://pubmed.ncbi.nlm.nih.gov/21763253/ 40. Pulsipher MA, Skinner R, McDonald GB, Hingorani S, Armenian SH, Cooke KR, et al. National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: the need for pediatric-specific long-term follow-up guidelines. Biol Blood Marrow Transplant [Internet]. 2012 Mar [cited 2022 Jun 19];18(3):334–47. Available from: https://pubmed. ncbi.nlm.nih.gov/22248713/ 41. Bresters D, Lawitschka A, Cugno C, Pötschger U, Dalissier A, Michel G, et al. Incidence and severity of crucial late effects after allogeneic HSCT for malignancy under the age of 3 years: TBI is what really matters. Bone Marrow Transplant [Internet]. 2016 Nov 1 [cited 2022 Jun 19];51(11):1482–9. Available from: https://pubmed. ncbi.nlm.nih.gov/27348540/ 42. Vrooman LM, Millard HR, Brazauskas R, Majhail NS, Battiwalla M, Flowers ME, et al. Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age. Biol Blood Marrow Transplant [Internet]. 2017 Aug 1 [cited 2022 Jun 19];23(8):1327–34. Available from: https://pubmed.ncbi.nlm.nih.gov/28461213/ 43. Bailey HK, Kappy MS, Giller RH, Gralla J. Time-course and risk factors of hypothyroidism following allogeneic hematopoietic stem cell transplantation (HSCT) in children conditioned with fractionated total body irradiation. Pediatr Blood Cancer [Internet]. 2008 Sep [cited 2022 Jun 19];51(3):405–9. Available from: https://pubmed.ncbi.nlm.nih.gov/18523993/ 44. Bakker B, Massa GG, Oostdijk W, Van Weel-Sipman MH, Vossen JM, Wit JM. Pubertal development and growth after total-body irradiation and bone marrow transplantation for haematological malignancies. Eur J Pediatr [Internet]. 2000 [cited 2022 Jun 20];159(1–2):31–7. Available from: https://pubmed.ncbi.nlm.nih. gov/10653326/ 45. Felicetti F, Manicone R, Corrias A, Manieri C, Biasin E, Bini I, et al. Endocrine late effects after total body irradiation in patients who received hematopoietic cell transplantation during childhood: a retrospective study from a single institution. J Cancer Res Clin Oncol [Internet]. 2011 Sep [cited 2022 Jun 20];137(9):1343–8. Available from: https://pubmed.ncbi.nlm.nih.gov/21769505/ 46. Socié G, Clift RA, Biaise D, Devergie A, Ringden O, Martin PJ, et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood [Internet]. 2001 Dec 15 [cited 2022 Jun 20];98(13):3569–74. Available from: https://pubmed.ncbi.nlm.nih. gov/11739158/ 47. Bernard F, Auquier P, Herrmann I, Contet A, Poiree M, Demeocq F, et al. Health status of childhood leukemia survivors who received hematopoietic cell transplantation after BU or TBI: an LEA study. Bone Marrow Transplant [Internet]. 2014 [cited 2022 Jun 20];49(5):709–16. Available from: https://pubmed.ncbi.nlm. nih.gov/24535128/ 48. Eissa HM, Lu L, Baassiri M, Bhakta N, Ehrhardt MJ, Triplett BM, et al. Chronic disease burden and frailty in survivors of childhood HSCT: a report from the St. Jude Lifetime Cohort Study. Blood Adv [Internet]. 2017 Nov 14 [cited 2022 Jun 20];1(24):2243–6. Available from: https://pubmed.ncbi.nlm.nih.gov/29296872/ 49. Calvo C, Ronceray L, Dhédin N, Buechner J, Troeger A, Dalle JH. Haematopoietic Stem Cell Transplantation in Adolescents and Young Adults With Acute Lymphoblastic Leukaemia: Special Considerations and Challenges. Front Pediatr. 2022 Jan 11;9:1538 50. Zucchetti G, Ciappina S, Bellini S, Dionisi Vici M, Spadea M, Biasin E, et al. The Creation of a Transition Protocol Survey for Childhood, Adolescent, and Young Adult Cancer Survivors in Transition from Pediatric to Adult Health Care in Italy. J Adolesc Young Adult Oncol [Internet]. 2022 Apr 1 [cited 2022 Jun 21];11(2):202–10. Available from: https://pubmed.ncbi.nlm.nih. gov/35076255/ 51. Baker KS, Bhatia S, Bunin N, Nieder M, Dvorak CC, Sung L, et al. NCI, NHLBI first international consensus conference on late effects after pediatric hematopoietic cell transplantation: state of the science, future directions. Biol Blood Marrow Transplant [Internet]. 2011 Oct [cited 2022 Jun 21];17(10):1424–7. Available from: https://pubmed.ncbi.nlm.nih.gov/21723224/ 52. Grupp SA, Maude SL, Shaw PA, Aplenc R, Barrett DM, Callahan C, et al. Durable Remissions in Children with Relapsed/ Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019). Blood [Internet]. 2015 Dec 3 [cited 2022 Jun 21];126(23):681–681. Available from: https:// ashpublications.org/blood/article/126/23/681/136212/Durable-Remissions-in-Children-with-Relapsed 53. Lee DW, Stetler-Stevenson M, Yuan CM, Shah NN, Delbrook C, Yates B, et al. Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation. Blood [Internet]. 2016 Dec 2 [cited 2022 Jun 21];128(22):218–218. Available from: https:// ashpublications.org/blood/article/128/22/218/100413/Long-TermOutcomes-Following-CD19-CAR-T-Cell 54. Summers C, Annesley C, Bleakley M, Dahlberg A, Jensen MC, Gardner R. Long Term Follow-up after SCRI-CAR19v1 Reveals Late Recurrences As Well As a Survival Advantage to Consolidation with HCT after CAR T Cell Induced Remission. Blood [Internet]. 2018 Nov 29 [cited 2022 Jun 21];132(Supplement 1):967–967. Available from: https://ashpublications.org/blood/article/132/Supplement 1/967/266133/Long-Term-Follow-up-after-SCRI-CAR19v1Reveals 55. Miyamura K, Yamashita T, Atsuta Y, Ichinohe T, Kato K, Uchida N, et al. High probability of follow-up termination among AYA survivors after allogeneic hematopoietic cell transplantation. Blood Adv [Internet]. 2019 Feb 12 [cited 2022 Jun 21];3(3):397–405. Available from: https://pubmed.ncbi.nlm.nih.gov/30728138/
RkJQdWJsaXNoZXIy ODUzNzk5